'; view Adial Pharmaceutical’s Chief Medical Officer Dr. Bankole Johnson Featured on NBC West Palm Beach, Florida Affiliate
'; view William Stilley, CEO of Adial Pharmaceuticals (NASDAQ: ADIL) sits down with BAF host Michelle Griego to discuss the company’s lead asset, AD04, as a potential genetically targeted treatment for alcohol and opioid use disorder.
'; view William Stilley, President and Chief Executive Officer, on the KSWB-TV FOX 5 Morning News in San Diego to discussing AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
'; view Adial’s Dr. Bankole Johnson Featured on The Doctors Channel discussing medicinal approaches to alcohol use disorder.
'; view Adial Pharmaceuticals’ Chairman, Professor Bankole Johnson, sits down with The Doctor’s Channel to speak about Alcohol Use Disorder and the massive toll it exacts on global health.
'; view Adial Pharmaceuticals Engages CRO to Begin Phase 3 Clinical Trials of AD04 for the Treatment of Alcohol Use Disorder
'; view Alcoholism: Is there a medicinal solution on the horizon? EHealth Radio invited Adial’s CEO, William Stilley, for an interview. Listen to the interview to learn more!
'; view Debunking the Myths About Alcoholism & Addiction, w/ Professor Bankole Johnson of the U of Maryland and HBO’s “Addiction” | EDB 73
'; view Treating Addiction Through Neuroscience Breakthroughs, with Prof. Bankole Johnson of the University of Maryland School of Medicine | EDB 72
'; view Leading internet business program CEO Money Interviews Adial CEO. Adial Pharmaceuticals is developing a genetically targeted treatment for alcohol addiction.
'; view Alcohol Use Disorder Drug Candidate from Adial Pharmaceuticals Shows Positive Stability Results
';
view
